Company Overview of GlycoRegImmune, Inc.
GlycoRegImmune, Inc., a biotech company, develops natural killer T (NKT) cells targeted therapies for liver disease, autoimmune disorders, and ischemic reperfusion injury. Its programs include NKT I cell inhibitors and NKT II cell modulators. The company is based in San Diego, California.
General Atomics Court
San Diego, CA 92121
Key Executives for GlycoRegImmune, Inc.
Similar Private Companies By Industry
|Protea Biosciences, Inc.||United States|
|Kemp Biotechnologies Inc.||United States|
|BioSphere Medical, Inc.||United States|
|MiTiHeart Corporation||United States|
|Repair Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact GlycoRegImmune, Inc., please visit glycoregimmune.com. Company data is provided by Capital IQ. Please use this form to report any data issues.